NCT04946864View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

August 12, 2024

Study Completion Date

October 1, 2024

Conditions
Breast CancerSolid Tumor, Adult
Interventions
DRUG

APG-2575

APG2575 monotherapy

DRUG

Palbociclib

combination APG2575+pablociclib

Trial Locations (7)

30322

Emory University Hospital, Atlanta

77030

MD Anderson, Houston

78229

Next Oncology, Austin

Next Oncology, San Antonio

Unknown

Sun Yat-Sen University Cancer Center, Guangzhou

Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangdong

Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT04946864 - A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | Biotech Hunter | Biotech Hunter